Macrophage derived foam cells are actively involved in the initial phase of atherosclerosis. Uptake of modified lipoprotein such as oxidized LDL (oxLDL) is a critical step for foam cell formation. CD36 is the major receptor mediating oxLDL uptake by macrophage. However, the molecular mechanism underlying CD36 mediated oxLDL uptake remains unclear. Here we reported that IRGM1 (IRGM in human), a member of immunity-related small GTPase family, is essential for the actin-dependent CD36 mediated oxLDL uptake by macrophage. IRGM/IRGM1 was highly expressed by macrophage around the atherosclerotic plaque and was up-regulated by oxLDL both in vitro and in vivo. Moreover loss of IRGM/ IRMG1 significantly decreased oxLDL uptake in both mouse and human. Furthermore, the IRGM1 knock-out mice displayed impaired CD36 internalization in macrophage, which was associated with the deficiency of F-actin polymerization. These results revealed a novel function of IRGM1 in regulating oxLDL uptake by macrophage during atherosclerosis.
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A therosclerosis is one of the most common chronic inflammatory vascular diseases in human 1 . The exact etiology of atherosclerosis remains unclear. Studies have shown that hyperlipidemia, one of the most important risk factors, is strongly associated with atherosclerosis 2 . The abnormal accumulation of lipoproteins, especially low density lipoprotein (LDL) in the arterial intima can be modified by factors such as oxygen free radicals from resident macrophage, which causes further recruitment of monocyte-derived macrophage 3 . These macrophages together with smooth muscle cells engulf the modified LDL, which in turn, transforms these cells into foam cells. Foam cells can release various pro-inflammatory cytokines and trigger an inflammatory cascade leading to atherosclerotic plaque formation 4 . Studies indicated that macrophage derived foam cells are important for the initial phase of the plaque formation during atherosclerosis 5 .
OxLDL accounts for large proportion of modified LDL that can be recognized by a variety of receptors, including the class A scavenger receptor SR-A and the class B scavenger receptor CD36 6 . CD36 is thought to be responsible for more than 50% of oxLDL uptake by mouse and human macrophages 7 . Upon exposure to oxLDL, CD36 together with oxLDL is internalized into punctuate organelles in the cytoplasm 8 . Further study has revealed that CD36 diffusion within linear confinement regions promoted unengaged receptor clustering, which is dependent on the cytoskeleton-mediated organization of receptor diffusion in the membrane and enhances CD36 responsiveness to ligand 9 . The internalization of CD36 together with the oxLDL is not only important for oxLDL uptake but is also crucial for signal transduction. However, little is known about how the actin-dependent CD36 internalization being regulated upon oxLDL activation. IRGM1 (IRGM in human) belongs to the immunity-related small GTPase family. Studies have revealed the multi-function of IRGM1 in diseases, including intracellular pathogen infection [10] [11] [12] [13] and autoimmune diseases 14, 15 and stroke 16 . Recent study also has shown that IRGM1 can facilitate macrophage migration through regulating actin polymerization 17 . Since actin also involved in oxLDL uptake, we asked whether IRGM1 is involved in oxLDL uptake by macrophage through actin-dependent CD36 internalization. To test this possibility, we tested the expression of IRGM/IRGM1 in atherosclerotic lesion and investigated how IRGM1/IRGM expression is regulated by oxLDL during atherosclerosis. The data demonstrated that IRGM1 plays a potent role in regulating the oxLDL uptake by macrophage via modulating the actin-dependent CD36 receptor-ligand internalization during atherosclerosis.
Results
IRGM/IRGM1 was highly expressed by foam cells in the lesion of atherosclerosis. To test whether IRGM1 was associated with the pathogenesis of atherosclerosis, we first examined the IRGM1 expression in the atherosclerotic plaque. ApoE 2/2 mice were fed with western diet to induce the mouse model of atherosclerosis. The expression of IRGM1 in the aortic arch was detected by western blot. Compared with the control mice, IRGM1 was highly expressed in the western diet-fed mice (Figure 1a , 1b and 1c). Costaining of IRGM1 with macrophage marker CD68 suggested that IRGM1 was expressed in the CD68 1 macrophage (Figure 1d ). Consistent with mice, IRGM was also highly expressed by the macrophage around the human AS plaque ( Figure 1e ).
OxLDL up-regulated IRGM/IRGM1 expression in macrophage. As oxLDL is an important factor that regulates macrophage response during atherosclerosis, also because IRGM1 is highly expressed by macrophages in atherosclerotic lesion, it is intriguing to assume that the IRGM1 expression can be regulated by oxLDL in macrophages during atherosclerosis. To test this hypothesis, peritoneal macrophages (PMW) and bone marrow derived macrophages (BMMW) were isolated from C57/B6 mice and treated with or without oxLDL for 48 hours. As shown in figure 2, IRGM1 was strongly up-regulated in both BMMW ( Figure 2a ) and PMW ( Figure S1a ) after oxLDL treatment compared with the nil condition (Figure 2a and S1a).
Consistently, we further confirmed this finding by using human THP1 cell derived macrophages ( Figure S1b and S1c) and human primary monocyte-derived macrophages (HMMW, Figure 2b ). Interestingly, using primary monocytes, we also found a positive correlation between IRGM expression and serum LDL level (Figure 2c ), indicating that the potential impact of LDL on IRGM expression in vivo. MiR196 has been reported that can direct regulate human IRGM expression 15 . We found that oxLDL strongly decreased miR196 expression ( Figure 2d ), which is consistent with a recent miRNAs profiling study using whole atherosclerotic plaque materials 18 . To further confirm that oxLDL regulates human IRGM expression through miR196, we transfected human macrophage with miR196 mimics. Compared to the control condition, miR196 mimics significantly decreased oxLDL induced IRGM expression in human macrophage (Figure 2e and Figure S2 ), indicating that oxLDL may regulate IRGM expression through down-regulation of miR196. These data together indicated that oxLDL induced IRGM/IRGM1 expression both in vitro and in vivo.
Loss of IRGM/IRGM1 decreased oxLDL uptake by macrophage both in vivo and in vitro. We next asked whether IRGM is involved in atherosclerosis pathogenesis in vivo. We fed Irgm 1/1 ApoE 2/2 and Irgm 1/2 ApoE 2/2 with western diet and compared the area of the aortic lesion. We showed a significant decrease of red-oil stained atherosclerotic lesion in the Irgm 1/2 ApoE 2/2 ( Figure 3a ). Moreover, after treating either Irgm1 1/1 or Irgm1 2/2 BMMW with oxLDL for 48 hours, we found a decrease of total cellular cholesterol ( Figure 3b ). Together, these data suggested that loss of IRGM1 decreased the foam cell formation in vivo and in vitro. Since the influx and efflux of the oxLDL together determine the formation of the foam cells, the decrease of foam cell formation may be due to the deficiency of oxLDL uptake or the increase of degraded oxLDL efflux or both. To address that question, we first compared oxLDL uptake by BMMW and PMW from either Irgm1 1/1 or Irgm1 2/2 mice using confocol microscopy and flow cytometry. Dil labeled oxLDL was used to trace the oxLDL up-take. To avoid the contamination of surface sticking oxLDL, cells were washed with ice-cold acid buffer before detection. Results from both BMMW (Figure 3c and 3d) and PMW ( Figure S3a and S3b) suggested that oxLDL uptake by macrophages was significantly impaired in the Irgm1 2/2 mice. To confirm this finding in human, small-interfering RNA (siRNA) specifically targeting human IRGM was used to knock down its expression in human primary monocyte-derived macrophages. Consistent with the finding in mice, oxLDL uptake by macrophages was lower in the IRGM-siRNA group, compared with control-siRNA treated group (Figure 3e and 3f ). We also measured the expression of the receptors related to oxLDL efflux such as ABCA1 and ABCG1. Interestingly, the natural expression of both ABCA1 and ABCG1 was significantly higher in the Irgm1 2/2 mice ( Figure S4 ). However, such differences were lost after oxLDL treatment. It has been reported that oxLDL can increase both ABCA1 and ABCG1 expression 19 . But in order to do that, the proper uptake of oxLDL is required for the signal transduction. So the inability to further increase ABCA1 and ABCG1 expression may due to the significant decrease of oxLDL uptake in the Irgm1 2/2 mice. These data indicated that IRGM1/IRGM is involved in the atherosclerosis pathogenesis and part of reason is through regulating oxLDL uptake by macrophage in both mouse and human.
IRGM1 regulates CD36 internalization via modulating F-actin polymerization. CD36 and scavenger receptor A are important for oxLDL uptake by macrophage. We next compared the expression of CD36 and SRA expression between Irgm1 1/1 and Irgm1 2/2 mice. We found that Irgm1 1/1 and Irgm1 2/2 mice have similar basic expression of CD36 and SRA ( Figure S5 ), which indicated that the impaired of oxLDL uptake in the Irgm1 2/2 mice is not due to the lower expression of these receptors. A recent study has demonstrated that CD36 linear diffusion and its receptor and signaling function is controlled by actin cytoskeleton 9 . Interestingly, studies have also revealed a role of IRGM1 in modulating cytoskeleton remodeling and membrane dynamics of macrophage 17 , which raised the possibility that IRGM1 may regulate the CD36 function via modulating actin cytoskeleton. To address this possibility, we first determined whether the function of CD36 in regulating the ligand recognition and internalization is impaired in the absence of IRGM1. As shown in figure 3 , upon binding to CD36 cross-linking antibody, CD36 internalization was remarkably suppressed in the Irgm1 2/2 mice as compared to Irgm1 1/1 mice (Figure 4a and 4b) . We then asked whether IRGM1 control the CD36 internalization via actin cytoskeleton. As shown in figure 4c and 4d, F-actin polymerization was significantly reduced in Irgm1 2/2 mice with or without oxLDL. As expected, in the wild type mice, oxLDL enhanced F-actin polymerization (Figure 4c and 4d) . Interestingly, unlike wild type mice, macrophage from Irgm1 2/2 mice was failed to increase F-actin polymerization after oxLDL treatment as we compared the ratio of actin MFI with or without oxLDL (Figure 4d ). These data demonstrated that IRGM1 regulates CD36 function via controlling the F-actin polymerization and, possibly, the CD36 diffusion and clustering on the membrane.
Discussion
Although the uptake of oxLDL by macrophage via scavenger receptors has been well established to be a critical step to foam cell formation and atherosclerosis, it remains poorly understood how this process being regulated. Our study has uncovered a novel function of IRGM/ IRGM1 as a regulator for the CD36-mediated oxLDL uptake by macrophage. During atherosclerosis, oxLDL up-regulates IRGM/IRGM1 in macrophage, which, in turn modulates the CD36 internalization of receptor-ligand complex, and promotes the oxLDL uptake. This positive feedback process involves the modulation of F-actin polymerization by IRGM1.
IRGM/IRGM1 has been implicated in a wide variety of biological functions, including host resistance to infections by intracellular bacterial and protozoan pathogens (e.g Mycobacteria and Toxoplasma gondii), stem cell development and maturation, T cell and neuronal autophagy, etc [10] [11] [12] [13] [14] [15] [16] . Further studies have demonstrated that Irgm1 is critically required for normal motility of activated macrophages and is pivotal in controlling the innate response to infection in vivo 17 . However, these observations have been confined to infectious conditions. Our study reveals a novel mechanism for Irgm1 in macrophages involved in atherosclerotic pathology.
It has been shown that the reciprocal interaction between oxLDL-CD36 and actin is important for oxLDL induced cellular and molecular events. On the one hand, through CD36, oxLDL can induce actin polymerization and control macrophage migration, polarity and locomotion 20, 21 . One the other hand, uptake of oxLDL by CD36 occurs by an actin-dependent pathway distinct from macropinocytosis 8 . OxLDL or antibody-induced clustering of CD36 triggers internalization of the receptor-ligand complex. Cytoskeleton perturbations that inhibited diffusion in linear confinement regions reduced receptor clustering in the absence of ligand and, following ligand addition, suppressed CD36-mediated signaling and internalization. Our results suggested that IRGM1 could be one of the important regulators for the actindriven CD36 internalization in macrophage. Although the precise mechanism connecting IRGM1 to the cytoskeleton remains to be determined, Taylor's group showed that IRGM1 can influence the activity of Ras-related C3 botulinun toxin subsetrate 1 (Rac1) in macrophages during activated condition, which is an important modulator for F-actin polymerization 17 . Further studies are needed to verify this possible mechanism.
In conclusion, for the first time we demonstrated a pathogenic role of IRGM/IRGM1 in atherosclerosis. The data expand our vision of IRGM1 as a potent regulator for macrophage motility and activity in Figure 3 | Loss of IRGM/IRGM1 decreases oxLDL uptake by macrophage. Irgm1 1/1 or Irgm1 2/2 mice were fed with western diet for 3 months. Aorta was isolated and stained with red oil. (a) The representative and the quantified data of atherosclerotic lesion (n 5 6/group, p 5 0.04). BMMW were isolated from either Irgm1 1/1 or Irgm1 2/2 mice. Ox-LDL or Dil-oxLDL was added for 48 hrs after isolation or induction. (b) Biochemical lipid quantitive assay was used to measure total cellular lipid. Dil-oxLDL was detected by either (c) confocal microscope (n 5 4/group, p 5 0.0004) or (d) flow cytometry (n 5 8/group, p 5 0.001). Human monocyte derived macrophage (HMMW) was transfected with either control-siRNA or IRGM-siRNA. IRGM-siRNA was validated by real-time PCR (, n 5 3, p 5 0.02). Dil-oxLDL uptake was measured by flow cytometry (f, n 5 3, p 5 0.04). Data are represented as mean 6 SEM.
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Methods
Cells. Peritoneal macrophages were recruited from Irgm1 1/1 and Irgm1 2/2 mice by injecting 2 ml 10% thioglycollic acid broth 3 days before collecting the cells with icecold RPMI. Cells were then rested on 24 well plates in RPMI with 10% fetal bovine serum for 24 hrs before experiments. For bone marrow-derived macrophages (BMM), femurs were dissected from Irgm1 1/1 and Irgm1 2/2 mice, BMMs were cultured in DMEM supplemented with conditioned medium collected from B16-GM-CSF cells for 5 days. Human THP1 cells were activated with 50 ng/ml PMA for 48 hrs before experiments. Healthy subjects were recruited from healthy volunteers. All subjects provided informed consent as approved by the HMU ethics review board. Human peripheral blood monocytes were purified by using CD14 beads (Miltenyi bio) based on manufacture's protocol and activated with 20 ng/ml hGMCSF (R&D system) for 4 days before experiments. OxLDL used in the experiments is from human peripheral blood LDL oxidized using Cu 2 SO 4 (oxidant) in PBS;Dil-oxLDL is from oxLDL labled with 1,19-dioctadecyl -3,3,39,39 -tetramethyl -indocarbocyanine perchlorate (Dil). The concentration of Dil-oxLDL is 50 mg/ml and the concentration of oxLDL is 25 mg/ml.
Mice. C57BL/6 (B6) mice were purchased from HFK BIOSCIENCE (Beijing). Irgm1 knock-out mice (Irgm1 2/2 ) were a gift by Dr. Gregory A. Taylor (Department of Medicine, Division of Geriatrics and Immunology, Duke University, USA) and were backcrossed to B6 background for 10 generations. ApoE 2/2 mice under the background of C57BL/6 were feed with western diet (TD.88137 Adjusted Calories Diet, from HFK BIOSCIENCE) for 12 weeks before experiments. All mice were housed in the animal facilities of the Harbin Medical University. All experimental procedures involved were performed according to protocols approved by the Institutional Animal Care and use Committee at the Institute of Genetics and Developmental Biology. Oil-red staining. The aortic arch from ApoE 2/2 mice feed with or without western diet was fixed for 24 hours in ice-cold 4% buffered paraform, After washed by PBS for 2 times, samples were stained with 1% of oil Red O solution (Sigma, Aldrich, USA) for 2hours. Samples were then washed for three times with PBS. Atherosclerostic lesions were measured by Image-Pro Plus 6.0 software with double-blinded assessment.
Western blot and Quantitative analysis. The protein concentration was measured by using BCA assay (P0012, Beyotime). Protein lysates were separated by SDS-PAGE and transferred to NC membranes. The membranes were blocked in non-fat-milk in TBS-T and were incubated with primary antibody overnight at 4uC. Then, after several washes, the membranes were incubated with secondary antibodies. After final Figure 4 | IRGM1 controls CD36 internalization by regulating actin polymerization. BMMW from either Irgm1 1/1 or Irgm1 2/2 mice was labeled with CD36 cross-linking antibody. Then, they were either left in 37uC to cross-link CD36 or on ice. Cells were then washed by cold acid wash buffer to deplete surface CD36. Confocal microscope and flow cytometry were used to detect and quantify CD36 internalization respectively. (a and b n 5 8/group, p 5 0.004). F-actin polymerization was detected by phalloidin-FITC in BMMW from either Irgm1 1/1 or Irgm1 2/2 mice with or without oxLDL. The fluorescence was measured by confocal microscope and quantified by flow cytometry (c and d, n 5 3, p 5 0.02). Data are represented as mean 6 SEM.
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Immunocytochemistry Staining. The sections were washed with PBS and then blocked with normal goat serum, 0.3% BSA, 0.05% saponin and 0.3% Triton X-100 in PBS for 1 hour. Then they were incubated at 4uC overnight with the primary antibody. The sections were later washed with PBS and incubated for 1 hour with secondary antibodies. The sections were then rinsed three times in PBS and mounted with GEL/Mounting Medium (MO1, Biomeda, USA) after nuclear staining. Fluorescence microscope (Nikon, Japan) and confocal microscope (Zeiss, Germany) were used to capture the images.
